Observational studyBMC cancer2026
Impact of underweight on patients receiving curative-intent anticancer therapy: analysis of a large oncology database in Saudi Arabia.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical effects of underweight status on short-term treatment-related morbidity in patients receiving curative-intent anticancer therapy remain unclear.
methodsWe conducted a retrospective observational cohort study using a comprehensive oncology database, including 2,504 consecutive patients with histologically confirmed malignancies treated between March 1 and June 30, 2020, at major cancer centers and outpatient clinics across Saudi Arabia. Patients who received curative-intent outpatient systemic anticancer therapy were eligible. Underweight (body mass index [BMI] < 18.5 kg/m²) and normal-weight patients were compared with respect to baseline characteristics, treatment patterns, and 30-day morbidity. Multivariable logistic regression was used to identify factors independently associated with morbidity.
resultsIn total, 787 patients met the eligibility criteria and were included in the analysis. Underweight patients were more frequently male (P < 0.001), whereas age (P = 0.764) and Eastern Cooperative Oncology Group (ECOG) performance status (P = 0.152) were similar between the BMI groups. Cancer stage distribution and curative treatment approach (neoadjuvant vs. adjuvant) did not differ significantly. Underweight patients were more likely to receive intravenous therapy (P = 0.005) and less likely to receive hormonal or targeted therapy. In unadjusted analyses, underweight patients had higher 30-day morbidity, with increased hospitalization (P = 0.023), emergency department visits (P = 0.034), and chemotherapy dose reductions (P = 0.004). After multivariable adjustment, underweight BMI was not independently associated with morbidity, whereas poorer ECOG performance status and treatment class were the strongest predictors. Intensive care unit admission rates did not differ between the groups.
conclusionsUnderweight status was associated with increased unadjusted short-term treatment-related morbidity among patients receiving curative-intent anticancer therapy. However, this association was largely explained by functional status and treatment-related factors. These findings highlight the importance of early risk stratification and proactive supportive care rather than BMI alone to optimize treatment tolerance in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.